US 12,029,735 B2
Polymorphic compounds and uses thereof
Stephen Gitu Machatha, Wilmington, MA (US); Charles Montgomery, Bolton, MA (US); Steven Krausert, Medford, MA (US); Jonathan James Loughrey, Edinburgh (GB); Hannah Ruth McLachlan, Edinburgh (GB); and Gregor Sneddon, Stirlingshire (GB)
Assigned to Aldeyra Therapeutics, Inc., Lexington, MA (US)
Filed by Aldeyra Therapeutics, Inc., Lexington, MA (US)
Filed on May 28, 2021, as Appl. No. 17/334,094.
Application 17/334,094 is a continuation of application No. PCT/US2020/031138, filed on May 1, 2020.
Claims priority of provisional application 62/841,900, filed on May 2, 2019.
Prior Publication US 2021/0393612 A1, Dec. 23, 2021
Int. Cl. A61K 31/47 (2006.01); C07D 215/38 (2006.01)
CPC A61K 31/47 (2013.01) [C07D 215/38 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A solid form of Compound 5:

OG Complex Work Unit Chemistry
of Form A having one or more peaks in its X-ray powder diffraction (XRPD) pattern selected from those at 13.9±0.2, 15.8±0.2, and 24.3±0.2 degrees 2-theta; or of Form B having one or more peaks in its XRPD selected from those 10.2±0.2, 17.0±0.2, and 28.8±0.2 degrees 2-theta.